Taysha Gene Therapies Announces Pricing of Initial Public Offering

Sept. 24, 2020 11:00 UTC

 

 
 

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (“Taysha”), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced the pricing of its initial public offering of 7,869,566 shares of common stock at a price to the public of $20.00 per share.

The shares are expected to begin trading on the Nasdaq Global Select Market under the symbol “TSHA” on September 24, 2020, and the offering is expected to close on September 28, 2020, subject to customary closing conditions. In addition, Taysha has granted the underwriters a 30-day option to purchase up to 1,180,434 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.

The offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526 or by emailing prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Jefferies, LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by emailing Prospectus_Department@Jefferies.com.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains certain forward-looking statements, including statements with regard to Taysha’s proposed securities offering. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the proposed securities offering discussed above will be consummated on the terms described or at all. Completion of the proposed securities offering and the terms thereof are subject to numerous factors, many of which are beyond the control of Taysha, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in Taysha’s filings with the Securities and Exchange Commission. Taysha undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Company Contact:
Niren Shah, Pharm.D., MBA
Taysha Gene Therapies
Nshah@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn@canalecomm.com

 
 

Source: Taysha Gene Therapies, Inc.

Back to news